The promises of quantitative systems pharmacology modelling for drug development

Computational and Structural Biotechnology Journal

Volumn 14, Issue , 2016, Pages 363-370

  Knight Schrijver, V R ^a   Chelliah, V ^b   Cucurull Sanchez, L ^c   Le Novere N ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Drug discovery; Modelling; New therapeutic entity; QSP; Quantitative systems pharmacology; Systems biology

Indexed keywords

ARSENALS; DRUG PRODUCTS;

DRUG DEVELOPMENT; DRUG DISCOVERY; MODELING; NEW THERAPEUTIC ENTITY; QUANTITATIVE SYSTEM PHARMACOLOGY; QUANTITATIVE SYSTEMS; SYSTEMS BIOLOGY; US FOOD AND DRUG ADMINISTRATION;

BIOLOGICAL SYSTEMS;

CYCLIC GMP; DOMPERIDONE; INTERLEUKIN 1BETA; KETOCONAZOLE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CARDIOTOXICITY; COMPUTER MODEL; COMPUTER SIMULATION; DRUG RESEARCH; HEART ARRHYTHMIA; MATHEMATICAL MODEL; MEDICAL SUBJECT HEADINGS; NEOPLASM; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOMETRICS; PRIORITY JOURNAL; QT PROLONGATION; QUANTITATIVE SYSTEMS PHARMACOLOGY; SHORT SURVEY; SYSTEMS BIOLOGY;

EID: 84991710984     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.1016/j.csbj.2016.09.002     Document Type: Short Survey

References (89)

1. [1] Pammolli, F., Magazzini, L., Riccaboni, M., The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10:6 (2011), 428–438, 10.1038/nrd3405.
2. [2] Frantz, S., 2003 approvals: a year of innovation and upward trends. Nat Rev Drug Discov 3:2 (2004), 103–105, 10.1038/nrd1327.
3. [3] Munos, B., Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:12 (2009), 959–968, 10.1038/nrd2961.
4. [4] Branch, S.K., Agranat, I., “New drug” designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. J Med Chem 57:21 (2014), 8729–8765, 10.1021/jm402001w.
5. [5] Scannell, J.W., Blanckley, A., Boldon, H., Warrington, B., Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:3 (2012), 191–200, 10.1038/nrd3681.
6. [6] Cohen, F.J., Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 4:1 (2005), 78–84, 10.1038/nrd1610.
7. [7] DiMasi J A, Innovation in the pharmaceutical industry: new estimates of R&D costs, In: R&D cost study briefing, Tufts Center for the Study of Drug Development (TCSDD), November 18, 2014. Available from: http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf.
8. [8] 2015 Biopharmaceutical research industry profile. Pharmaceutical Research and Manufacturers of America (PhRMA), 2015. Available from: http://www.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf.
9. [9] Summary, Novel Drugs, U.S. Food and Drug Administration Center of Drug Evaluation and Research, 2015., 2015 http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM485053.pdf Available from.
10. [10] Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nature reviews Drug discovery 3:8 (2004), 711–716, 10.1038/nrd1470.
11. [11] Waring, M.J., Arrowsmith, J., Leach, A.R., Leeson, P.D., Mandrell, S., Owen, R.M., An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14:7 (2015), 475–486, 10.1038/nrd4609.
12. [12] Hay, M., Thomas, D.W., Craighead, J.L., Economides, C., Rosenthal, J., Clinical development success rates for investigational drugs. Nat Biotechnol 32:1 (2014), 40–51, 10.1038/nbt.2786.
13. [13] Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:6 (2014), 419–431, 10.1038/nrd4309.
14. [14] Marshall, S., Burghaus, R., Cosson, V., Cheung, S., Chenel, M., Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT,: Pharmacometrics & Syst Pharmacol 5:3 (2016), 93–122, 10.1002/psp4.12049.
15. [15] Visser, S.A.G., de Alwis, D.P., Kerbusch, T., Stone, J.A., Allerheiligen, S.R.B., Implementation of quantitative and systems pharmacology in large pharma. CPT, Pharmacometrics Syst Pharmacol, 3(10), 2014, e142, 10.1038/psp.2014.40.
16. [16] Milligan, P.A., Brown, M.J., Marchant, B., Martin, S.W., van der Graaf, P.H., Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 93:6 (2013), 502–514, 10.1038/clpt.2013.54.
17. [17] Visser, S.A.G., Manolis, E., Danhof, M., Kerbusch, T., Modeling and simulation at the interface of nonclinical and early clinical drug development. CPT: Pharmacometrics & Syst Pharmacol, 2(2), 2013, e30, 10.1038/psp.2013.3.
18. [18] Visser, S.A., Aurell, M., Jones, R.D., Schuck, V.J., Egnell, A.-C., Model-based drug discovery: implementation and impact. Drug Discov Today 18:15-16 (2013), 764–775, 10.1016/j.drudis.2013.05.012.
19. [19] Brodland, G.W., How computational models can help unlock biological systems. Semin Cell Dev Biol 47-48 (2015), 62–73, 10.1016/j.semcdb.2015.07.001.
20. [20] Kumar, N., Hendriks, B.S., Janes, K.A., de Graaf, D., Lauffenburger, D.A., Applying computational modeling to drug discovery and development. Drug Discov Today 11:17-18 (2006), 806–811, 10.1016/j.drudis.2006.07.010.
21. [21] Teorell, T., Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration. Arch Int Pharmacodyn Ther 57 (1937), 205–225.
22. [22] Teorell, T., Kinetics of distribution of substances administered to the body, II: the intravascular modes of administration. Arch Int Pharmacodyn Ther 57 (1937), 226–240.
23. [23] Paalzow, L.K., Torsten teorell, the father of pharmacokinetics. Ups J Med Sci 100:1 (1995), 41–46, 10.3109/03009739509178895.
24. [24] Benet, L.Z., Foreword. Cutler, N.R., Sramek, J.J., Narang, P.K., (eds.) Pharmacodynamics and drug development: perspectives in clinical pharmacology, 1994, Chichester: Wiley, xiii–xv.
25. [25] Rohatagi, S., Martin, N.E., Barrett, J.S., Applications of pharmacokinetic principles in drug development. Ch. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development, 2004, Springer, US, Boston, MA, 333–372, 10.1007/978-1-4419-9216-1_11.
26. [26] Edginton, A.N., Theil, F.-P., Schmitt, W., Willmann, S., Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:9 (2008), 1143–1152, 10.1517/17425255.4.9.1143.
27. [27] Espié, P., Tytgat, D., Sargentini-Maier, M.-L., Poggesi, I., Watelet, J.-B., Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 41:3 (2009), 391–407, 10.1080/10837450902891360.
28. [28] Lee, J.Y., Garnett, C.E., Gobburu, J.V., Bhattaram, V.A., Brar, S., Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 50:10 (2011), 627–635, 10.2165/11593210-000000000-00000.
29. [29] Bhattaram, V.A., Bonapace, C., Chilukuri, D.M., Duan, J.Z., Garnett, C., Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther 81:2 (2007), 213–221, 10.1038/sj.clpt.6100051.
30. [30] Bhattaram, V.A., Booth, B.P., Ramchandani, R.P., Beasley, B.N., Wang, Y., Tandon, V., Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 7:3 (2005), E503–E512, 10.1208/aapsj070351.
31. [31] Hodgkin, A.L., Huxley, A.F., A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol (Lond) 117:4 (1952), 500–544.
32. [32] Mabry, P.L., Making sense of the data explosion: the promise of systems science. Am J Prev Med 40:5 Suppl 2 (2011), S159–161, 10.1016/j.amepre.2011.02.001.
33. [33] Kitano, H., Systems biology: a brief overview. Science 295:5560 (2002), 1662–1664, 10.1126/science.1069492.
34. [34] Albert, R., Network inference, analysis, and modeling in systems biology. Plant Cell 19:11 (2007), 3327–3338, 10.1105/tpc.107.054700.
35. [35] Allerheiligen, S.R.B., Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther 88:1 (2010), 135–137, 10.1038/clpt.2010.81.
36. [36] Sorger, P.K., Allerheiligen, S.R., Abernethy, D.R., Altman, R.B., Brouwer, K.L., Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP workshop group, 2011, NIH Bethesda, 1–48.
37. [37] Nyman, E., Rozendaal, Y.J.W., Helmlinger, G., Hamrén, B., Kjellsson, M.C., Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes. Interface Focus, 6(2), 2016, 20150075, 10.1098/rsfs.2015.0075.
38. [38] Agoram, B.M., Demin, O., Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discov Today 16:23-24 (2011), 1031–1036, 10.1016/j.drudis.2011.10.001.
39. [39] Peterson, M.C., Riggs, M.M., FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment?. CPT Pharmacometrics Syst Pharmacol, 4(3), 2015, e00020, 10.1002/psp4.20.
40. [40] van der Graaf, P.H., Benson, N., Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm Res 28:7 (2011), 1460–1464, 10.1007/s11095-011-0467-9.
41. [41] Bai, J.P.F., Fontana, R.J., Price, N.D., Sangar, V., Systems pharmacology modeling: an approach to improving drug safety. Biopharm Drug Dispos 35:1 (2013), 1–14, 10.1002/bdd.1871.
42. [42] Le Novère, N., Bornstein, B., Broicher, A., Courtot, M., Donizelli, M., BioModels database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res 34:Database issue (2006), D689–D691, 10.1093/nar/gkj092.
43. [43] Chelliah, V., Juty, N., Ajmera, I., Ali, R., Dumousseau, M., Biomodels: ten-year anniversary. Nucleic Acids Res 43 (2015), D542–D548, 10.1093/nar/gku1181.
44. [44] Ajmera, I., Swat, M., Laibe, C., Novère, N.L., Chelliah, V., The impact of mathematical modeling on the understanding of diabetes and related complications. CPT: Pharmacometrics & Syst Pharmacol, 2(7), 2013, e54, 10.1038/psp.2013.30.
45. [45] Peterson, M.C., Riggs, M.M., A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46:1 (2010), 49–63, 10.1016/j.bone.2009.08.053.
46. [46] Khurana, M., Mehrotra, N., Zadezensky, I., Clinical pharmacology assessment: adequacy of natpara dosage regimen in treatment of hypothyroidism. Endocrinologic and metabolic drugs advisory committee meeting 2014, endocrinologic and metabolic drugs advisory committee, office of clinical pharmacology, 2014, 136–144.
47. [47] Kazmi, N., Hossain, M.A., Phillips, R.M., A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport. IEEE/ACM Trans Comput Biol Bioinform 9:6 (2012), 1595–1606, 10.1109/TCBB.2012.118.
48. [48] Au, J.L., Yeung, B.Z., Wientjes, M.G., Lu, Z., Wientjes, M.G., Delivery of cancer therapeutics to extracellular and intracellular targets: determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev 97 (2016), 280–301, 10.1016/j.addr.2015.12.002.
49. [49] Sharan, S., Woo, S., Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach. CPT Pharmacometrics Syst Pharmacol, 3, 2014, e139, 10.1038/psp.2014.36.
50. [50] Sharan, S., Woo, S., Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol, 6, 2015, 33, 10.3389/fphar.2015.00033.
51. [51] Zhu, X., Straubinger, R.M., Jusko, W.J., Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42:5 (2015), 477–496, 10.1007/s10928-015-9429-x.
52. [52] Tetralogic pharmaceuticals, dose escalation, combination chemotherapy safety study of birinapant (TL32711), in subjects with advanced or metastatic solid tumors. ClinicalTrials.gov [Internet], 2010 - [cited 2016 April 18], Bethesda (MD): National Library of Medicine (US) Available from https://clinicaltrial s.gov/ct2/show/NCT01188499 NLM Identifier: NCT01188499.
53. [53] Geerts, H., Spiros, A., Roberts, P., Carr, R., Has the time come for predictive computer modeling in CNS drug discovery and development?. CPT: Pharmacometrics & Syst Pharmacol, 1(11), 2012, e16, 10.1038/psp.2012.17.
54. [54] Franco, R., Cedazo-Minguez, A., Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?. Front Pharmacol, 5, 2014, 146, 10.3389/fphar.2014.00146.
55. [55] Geerts, H., Of mice and men. CNS Drugs 23:11 (2009), 915–926, 10.2165/11310890-000000000-00000.
56. [56] Nicholas, T., Duvvuri, S., Leurent, C., Raunig, D., Rapp, T., Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial. Adv in Alzheimer's Dis 02:03 (2013), 83–98, 10.4236/aad.2013.23012.
57. [57] Roberts, P., Spiros, A., Geerts, H., A humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in Parkinson's disease. Front Pharmacol, 7, 2016, 10.3389/fphar.2016.00006.
58. [58] Yang, J.H., Saucerman, J.J., Computational models reduce complexity and accelerate insight into cardiac signaling networks. Circ Res 108:1 (2011), 85–97, 10.1161/circresaha.110.223602.
59. [59] Lee, B.-K., Computational fluid dynamics in cardiovascular disease. Korean Circ J, 41(8), 2011, 423, 10.4070/kcj.2011.41.8.423.
60. [60] McGinty, S., A decade of modelling drug release from arterial stents. Math Biosci 257 (2014), 80–90, 10.1016/j.mbs.2014.06.016.
61. [61] Garmaroudi, F.S., Handy, D.E., Liu, Y.-Y., Loscalzo, J., Systems pharmacology and rational polypharmacy: nitric oxide-cyclic GMP signaling pathway as an illustrative example and derivation of the general case. PLOS Comput Biol, 12(3), 2016, e1004822, 10.1371/journal.pcbi.1004822.
62. [62] Davies, M.R., Wang, K., Mirams, G.R., Caruso, A., Noble, D., Recent developments in using mechanistic cardiac modelling for drug safety evaluation. Drug Discov Today, 2016, 10.1016/j.drudis.2016.02.003 In Press.
63. [63] Mishra, H., Polak, S., Jamei, M., Rostami-Hodjegan, A., Interaction between domperidone and ketoconazole: toward prediction of consequent QTc prolongation using purely in vitro information. CPT Pharmacometrics Syst Pharmacol, 3(8), 2014, e130, 10.1038/psp.2014.26.
64. [64] Fitzgerald, J.B., Schoeberl, B., Nielsen, U.B., Sorger, P.K., Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2:9 (2006), 458–466, 10.1038/nchembio817.
65. [65] Palmér, R., Nyman, E., Penney, M., Marley, A., Cedersund, G., Agoram, B., Effects of IL-1β-blocking therapies in type 2 diabetes mellitus: a quantitative systems pharmacology modeling approach to explore underlying mechanisms. CPT Pharmacometrics Syst Pharmacol, 3(6), 2014, e118, 10.1038/psp.2014.16.
66. [66] Palsson, S., Hickling, T.P., Bradshaw-Pierce, E.L., Zager, M., Jooss, K., The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. BMC Syst Biol, 7, 2013, 95, 10.1186/1752-0509-7-95.
67. [67] Demin, O., Karelina, T., Svetlichniy, D., Metelkin, E., Speshilov, G., Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst Pharmacol, 2, 2013, e74, 10.1038/psp.2013.49.
68. [68] Dunn, S.-J., Näthke, I.S., Osborne, J.M., Computational models reveal a passive mechanism for cell migration in the crypt. PloS ONE, 8(11), 2013, e80516, 10.1371/journal.pone.0080516.
69. [69] Leber, A., Viladomiu, M., Hontecillas, R., Abedi, V., Philipson, C., Hoops, S., Systems modeling of interactions between mucosal immunity and the gut microbiome during clostridium difficile infection. PLOS ONE, 10(7), 2015, e0134849, 10.1371/journal.pone.0134849.
70. [70] Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K.-Y., Kitano, H., Software for systems biology: from tools to integrated platforms. Nat Rev Genet, 2011, 10.1038/nrg3096.
71. [71] Ghosh, S., Matsuoka, Y., Asai, Y., Hsin, K.-Y., Kitano, H., Toward an integrated software platform for systems pharmacology. Biopharm Drug Dispos 34:9 (2013), 508–526, 10.1002/bdd.1875.
72. [72] Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:1 (2000), 27–30, 10.1093/nar/28.1.27.
73. [73] Joshi-Tope, G., Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 33:Database issue (2004), D428–D432, 10.1093/nar/gki072.
74. [74] Shannon, P., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:11 (2003), 2498–2504, 10.1101/gr.1239303.
75. [75] Funahashi, A., Morohashi, M., Kitano, H., Tanimura, N., CellDesigner: a process diagram editor for gene-regulatory and biochemical networks. BIOSILICO, 1:5 (2003), 159–162, 10.1016/s1478-5382(03)02370-9.
76. [76] Hoops, S., Sahle, S., Gauges, R., Lee, C., Pahle, J., Simus, N., COPASI-a COmplex PAthway SImulator. Bioinformatics 22:24 (2006), 3067–3074, 10.1093/bioinformatics/btl485.
77. [77] Core Team, R., R: a language and environment for statistical computing. R foundation for statistical computing, 2016, Vienna, Austria https://www.R-project.org/.
78. [78] Eaton, J.W., Bateman, D., Hauberg, S., Wehbring, R., GNU octave version 4.0.0 manual: a high-level interactive language for numerical computations. 2015 http://www.gnu.org/software/octave/doc/interpreter.
79. [79] MATLAB and Simulink product families., 2016, The MathWorks, Inc., Natick, Massachusetts, United States.
80. [80] Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., Rostami-Hodjegan, A., The simcyp ® population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:2 (2009), 211–223, 10.1517/17425250802691074.
81. [81] Leil, T.A., Ermakov, S., Editorial: the emerging discipline of quantitative systems pharmacology. Front Pharmacol, 6, 2015, 129, 10.3389/fphar.2015.00129.
82. [82] Hucka, M., Finney, A., Sauro, H.M., Bolouri, H., Doyle, J.C., The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19:4 (2003), 524–531, 10.1093/bioinformatics/btg015.
83. [83] Swat, M.J., Moodie, S., Wimalaratne, S.M., Kristensen, N.R., Lavielle, M., Pharmacometrics markup language (PharmML): opening new perspectives for model exchange in drug development. CPT Pharmacometrics Syst Pharmacol 4:6 (2015), 316–319, 10.1002/psp4.57.
84. [84] Harnisch, L., Matthews, I., Chard, J., Karlsson, M., Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development. CPT Pharmacometrics Syst Pharmacol, 2, 2013, e34, 10.1038/psp.2013.10.
85. [85] Hutchinson, L., Kirk, R., High drug attrition rates—where are we going wrong?. Nat Rev Clin Oncol 8:4 (2011), 189–190, 10.1038/nrclinonc.2011.34.
86. [86] Cucurull-Sanchez, L., Spink, K.G., Moschos, S.A., Relevance of systems pharmacology in drug discovery. Drug Discov Today 17:13-14 (2012), 665–670, 10.1016/j.drudis.2012.01.015.
87. [87] Benson, N., van der Graaf, P.H., The rise of systems pharmacology in drug discovery and development. Future Med Chem 6:16 (2014), 1731–1734, 10.4155/fmc.14.66.
88. [88] Leil, T.A., Bertz, R., Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Front Pharmacol, 5, 2014, 10.3389/fphar.2014.00247.
89. [89] Vicini, P., van der Graaf, P.H., Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?. Clin Pharmacol Ther 93:5 (2013), 379–381, 10.1038/clpt.2013.40.